ADMA Biologics (ADMA) vs Denali Therapeutics (DNLI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed ADMA Biologics (ADMA) over the past year, gaining 28.6% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with -57.9% for DNLI. Denali Therapeutics is the larger company by market cap ($2.94 billion vs $2.28 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | DNLI |
|---|---|---|
| Share price | $10.19 | $18.41 |
| Market cap | $2.28B | $2.94B |
| 1-day change | +0.49% | -3.92% |
| YTD return | -44.41% | +16.05% |
| 1-year return | -27.52% | +28.59% |
| 5-year return | +821.82% | -57.95% |
| P/E ratio (TTM) | 14.56 | — |
| Forward P/E | 10.80 | — |
| EPS (TTM) | $0.70 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | — | $-512.54M |
| 52-week high | $20.46 | $27.30 |
| 52-week low | $7.21 | $13.75 |
| Distance from 52-week high | -50.19% | -32.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +66.83% | +95.88% |
| Average volume | 2.63M | 1.61M |
| Shares outstanding | 223.98M | 159.85M |
| Employees | 640 | 503 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed ADMA by 56.1 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
ADMA vs DNLI FAQ
Which is bigger, ADMA Biologics or Denali Therapeutics?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $2.94B compared with $2.28B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or DNLI?
DNLI returned +28.59% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Denali Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.